Men's health research priorities in men with multiple sclerosis
Multiple Sclerosis Journal - Experimental, Translational and Clinical · Published 2026-04-01 · DOI 10.1177/20552173261447999
Free full text
Authors being retrieved — see the publisher record. https://doi.org/10.1177/20552173261447999
Abstract
Background Men with multiple sclerosis (MwMS) experience distinct health, symptoms, and disease progression patterns compared to women, necessitating targeted research and clinical approaches. Objectives We aimed to evaluate the perceived relative importance of topics in men's health for future research in this area and sought to understand research priorities and sources of information among MwMS. Methods In a cross-sectional survey, male participants in the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry ranked research priorities among 14 men's health-specific topics. The online survey contained additional questions on information-seeking behavior and preferences, adapted from the 2007 Health Information National Trends survey. Multivariate linear regression examined factors associated with topic rankings. Results Of 8567 participants invited, 5098 (59.3%) responded, of whom 896 were males; 775 were included. Sexual function/dysfunction ranked as the highest priority men's health topics followed by prostate cancer/cancer screening, benign prostatic hyperplasia, and low testosterone. These topics were the most frequently searched topics by participants, and the most frequent source used was mass media. Conclusion We identified priority research topics for men's health issues in MS from the perspective of MwMS. Continued engagement of MwMS as partners in refining research questions and communicating results will ensure the outcomes remain relevant to those who seek them.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2026
Related articles
- Comorbidities in newly diagnosed multiple sclerosis patients: A population-based register study in Finland · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Hypogammaglobulinemia and infection rates in patients with multiple sclerosis treated with ocrelizumab for up to six years: A real-world single-center study · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal
- Real-world safety and effectiveness of ofatumumab in multiple sclerosis: A clinic-based study in Australia · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Music therapy with a monochord in multiple sclerosis (“MUTIMS”): A randomized, controlled, rater-blinded trial · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal
- Deep cervical lymph node volume decreases following B-cell depletion therapy · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal
- Establishing demographic-based normative values for neurofilament light chain and glial fibrillary acidic protein in serum and plasma samples · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Feasibility and preliminary outcomes of a remotely-delivered exercise training intervention for English-speaking Hispanics/Latinos with multiple sclerosis: Results from the FERLA MS study · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Discrepancy between subjective and objective cognitive function in multiple sclerosis and association with mood, fatigue, and pain · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Baricitinib triggering a central nervous system inflammatory-demyelinating disease: A case report · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Analysis of an innovative fluid biomarker panel for early prediction of progression independent of relapse activity in multiple sclerosis · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal